Verapamil-associated Stevens-Johnson syndrome.
Stevens-Johnson syndrome (SJS) is a complication infrequently associated with the use of calcium-channel blocking agents. A 59-year-old woman developed symptoms typical of SJS approximately ten days following the initiation of sustained-release verapamil for hypertension management. Symptoms consisted of a generalized red macular rash associated with swelling of the face, tongue, lips, and mouth as well as a fever of 40 degrees C. Resolution of symptoms began approximately four days after verapamil discontinuation. Rechallenge with verapamil was not performed. Although SJS appears to be a rare adverse effect of this drug, the potential complications warrant the inclusion of SJS in the differential diagnosis of patients presenting with malaise, fever, rash, and a history of verapamil ingestion.
Lin
A Y
AY
College of Pharmacy and Allied Health Professions, St John's University, Jamaica, NY 11439.
Baker
B A
BA
D005260:Female; D006801:Humans; D008875:Middle Aged; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use
D014700:Verapamil